The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery—Personal Remarks and Future Prospects
Open accessAbstract
This Special Issue on the enhanced permeability and retention (EPR) effect commemorates the 35th anniversary of its discovery, the original 1986 Matsumura and Maeda finding being published in Cancer Research as a new concept in cancer chemotherapy. My review here describes the history and heterogeneity of the EPR effect, which involves defective tumor blood vessels and blood flow. We reported that restoring obstructed tumor blood flow overcomes impaired drug delivery, leading to improved EPR effects. I also discuss gaps between small animal cancers used in experimental models and large clinical cancers in humans, which usually involve heterogeneous EPR effects, vascular abnormalities in multiple necrotic foci, and tumor emboli. Here, I emphasize arterial infusion of oily formulations of nanodrugs into tumor-feeding arteries, which is the most tumor-selective drug delivery method, with tumor/blood ratios of 100-fold. This method is literally the most personalized medicine because arterial infusions differ for each patient, and drug doses infused depend on tumor size and anatomy in each patient. Future developments in EPR effect-based treatment will range from chemotherapy to photodynamic therapy, boron neutron capture therapy, and therapies for free radical diseases. This review focuses on our own work, which stimulated numerous scientists to perform research in nanotechnology and drug delivery systems, thereby spawning a new cancer treatment era.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, many clinical cancers such as late-stage tumors and refractory tumors are associated with poor blood flow due to the coagulation and thrombi formation exhibiting poor EPR effect [7,8,9,10,11,12].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The EPR effect can be enhanced by modifying vascular intermediaries such as angiotensin II, nitroglycerin or NO, CO, and enzyme inhibitors [7,8,9,10].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“However, because tumor blood flow and vascular permeability are significantly varied from each other, the EPR effect may not be beneficial for all solid tumors.194”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationAnalysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Fang, J. Q., Nakamura, H., & Maeda, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,573
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Self-citationMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Self-citationPrabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W. C., Farokhzad, O. C., Barry, S. T., Gabizón, A., Grodzinski, P. A., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,493
Self-citationGabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Self-citationTumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 997
Self-citationMacromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 815
Self-citationFang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Self-citationSMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Self-citationMaeda, H., Fang, J. Q., Inutsuka, T., & Kitamoto, Y. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00271-0 · Cited by 537
Self-citationMaeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491
Self-citationNoguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., & Maeda, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00563.x · Cited by 470
Self-citationDetermination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Delivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S. M., Tosi, G., Spring, K., Åslund, A., Pottier, A., Schiffelers, R. M., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 435
Oxygen Radicals in Influenza-Induced Pathogenesis and Treatment with Pyran Polymer-Conjugated SOD
Oda, T., Akaike, T., Hamamoto, T., Suzuki, F., Hirano, T., & Maeda, H. (1989) · Science · doi:10.1126/science.2543070 · Cited by 418
Self-citationLynch, H. T., Kimberling, W. J., Albano, W. A., Lynch, J. F., Biscone, K. A., Schuelke, G. S., Sandberg, A. A., Lipkin, M., Deschner, E. E., Mikol, Y. B., et al. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4 · Cited by 400
Self-citationLee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I. E., Ma, C. X., LoRusso, P. M., Münster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 397
Nitric oxide and virus infection
Akaike, T., & Maeda, H. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00142.x · Cited by 362
Self-citationMaeda, H., Tsukigawa, K., & Fang, J. Q. (2015) · Microcirculation · doi:10.1111/micc.12228 · Cited by 356
Self-citationKonno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Morinaga, T., Mochinaga, M., Hiraoka, T., & Yokoyama, I. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90028-7 · Cited by 342
Self-citationAkaike, T., Ando, M., Oda, T., Doi, T., Ijiri, S., Araki, S., & Maeda, H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114499 · Cited by 333
Self-citationMaeda, H. (2012) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.88.53 · Cited by 291
Self-citationIwai, K., Maeda, H., & Konno, T. (1984) · PubMed · Cited by 284
Self-citationFang, J. Q., Sawa, T., Akaike, T., Akuta, T., Sahoo, S. K., Greish, K. F., Hamada, A., & Maeda, H. (2003) · PubMed · Cited by 221
Self-citationSMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (1991) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(91)90040-j · Cited by 214
Self-citationWu, J., Akaike, T., & Maeda, H. (1998) · PubMed · Cited by 212
Self-citationMolla, A., Yamamoto, T., Akaike, T., Miyoshi, S.-I., & Maeda, H. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81661-1 · Cited by 194
Self-citationNagamitsu, A., Greish, K. F., & Maeda, H. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp074 · Cited by 180
Self-citationEnhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application
Seki, T., Fang, J. Q., & Maeda, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01323.x · Cited by 179
Self-citationArterial thromboembolic events preceding the diagnosis of cancer in older persons
Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Okin, P. M., Tagawa, S. T., Panageas, K. S., & DeAngelis, L. M. (2019) · Blood · doi:10.1182/blood-2018-06-860874 · Cited by 179
8-Nitroguanosine formation in viral pneumonia and its implication for pathogenesis
Akaike, T., Okamoto, S., Sawa, T., Yoshitake, J., Tamura, F., Ichimori, K., Miyazaki, K., Sasamoto, K., & Maeda, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0235623100 · Cited by 170
Self-citationFree Radicals in Viral Pathogenesis: Molecular Mechanisms Involving Superoxide and NO
Akaike, T., Suga, M., & Maeda, H. A. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44206 · Cited by 169
Self-citationInvolvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue
Matsumura, Y., Kimura, M., Yamamoto, T., & Maeda, H. (1988) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1988.tb01563.x · Cited by 163
Self-citationMaeda, H. (2013) · Cancer Science · doi:10.1111/cas.12152 · Cited by 162
Self-citationThe beginning of the end of the nanomedicine hype
Park, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.044 · Cited by 158
Enhanced Vascular Permeability in Solid Tumor Involving Peroxynitrite and Matrix Metalloproteinases
Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A., & Maeda, H. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01114.x · Cited by 152
Self-citationPolymer therapeutics and the EPR effect
Maeda, H. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1365878 · Cited by 152
Self-citationMatsumoto, K., Yamamoto, T., Kamata, R., & Maeda, H. (1984) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a134892 · Cited by 133
Self-citationMaeda, H., Matsumura, Y., & Kato, H. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37555-0 · Cited by 128
Self-citationInvestigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy
Ding, Y., Xu, Y., Yang, W., Niu, P., Li, X., Chen, Y., Li, Z., Liu, Y., An, Y., Liu, Y., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100970 · Cited by 127
The solid progress of nanomedicine
Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H. F., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00743-2 · Cited by 125
Tackle the free radicals damage in COVID-19
Wu, J. (2020) · Nitric Oxide · doi:10.1016/j.niox.2020.06.002 · Cited by 117
Role of Nitric Oxide in Pathogenesis of Herpes Simplex Virus Encephalitis in Rats
Fujii, S., Akaike, T., & Maeda, H. (1999) · Virology · doi:10.1006/viro.1999.9610 · Cited by 112
Self-citationNakamura, H., Etrych, T., Chytil, P., Ohkubo, M., Fang, J. Q., Ulbrich, K., & Maeda, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.011 · Cited by 109
Self-citationGaspar, H. B. (2009) · Biologics · doi:10.2147/btt.s3103 · Cited by 104
Kinin‐generating Cascade in Advanced Cancer Patients and in vitro Study
Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T., & Maeda, H. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01910.x · Cited by 104
Self-citationKamata, R., Yamamoto, T., Matsumoto, K., & Maeda, H. (1985) · Infection and Immunity · doi:10.1128/iai.48.3.747-753.1985 · Cited by 102
Self-citationIslam, W., Fang, J. Q., Imamura, T., Etrych, T., Šubr, V., Ulbrich, K., & Maeda, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0696 · Cited by 97
Self-citationViral mutation accelerated by nitric oxide production during infection in vivo
Akaike, T., Fujii, S., Kato, A., Yoshitake, J., Miyamoto, Y., Sawa, T., Okamoto, S., Suga, M., Asakawa, M., Nagai, Y., et al. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1447 · Cited by 95
Self-citationMayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K. F., Nakamura, H., Derdak, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055723 · Cited by 94
Self-citationKamisaki, Y., Wada, H., Yagura, T., Matsushima, A., & Inada, Y. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32435-3 · Cited by 93
Dozono, H., Yanazume, S., Nakamura, H., Etrych, T., Chytil, P., Ulbrich, K., Fang, J. Q., Arimura, T., Douchi, T., Kobayashi, H., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0379-4 · Cited by 88
Self-citationSawa, T., Wu, J., Akaike, T., & Maeda, H. (2000) · PubMed · Cited by 85
Self-citationKallikrein–kinin in infection and cancer
Maeda, H., Wu, J., Okamoto, T., Maruo, K., & Akaike, T. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00104-6 · Cited by 83
Self-citationEnhancing Tumor Drug Distribution With Ultrasound-Triggered Nanobubbles
Nittayacharn, P., Yuan, H., Hernandez, C., Bielecki, P. A., Zhou, H., & Exner, A. A. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.004 · Cited by 78
Nakamura, H., Liao, L., Hitaka, Y., Tsukigawa, K., Šubr, V., Fang, J. Q., Ulbrich, K., & Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.017 · Cited by 67
Self-citationNitric Oxide as an Endogenous Mutagen for Sendai Virus without Antiviral Activity
Yoshitake, J., Akaike, T., Akuta, T., Tamura, F., Ogura, T., Esumi, H., & Maeda, H. (2004) · Journal of Virology · doi:10.1128/jvi.78.16.8709-8719.2004 · Cited by 61
Self-citationKhan, M. S., Hwang, J., Lee, K., Choi, Y., Seo, Y., Jeon, H., Hong, J. W., & Choi, J. H. (2019) · Cancers · doi:10.3390/cancers11101464 · Cited by 60
Oda, T., & Maeda, H. (1987) · PubMed · Cited by 54
Self-citationDaruwalla, J., Nikfarjam, M., Greish, K. F., Malcontenti‐Wilson, C., Muralidharan, V., Christophi, C., & Maeda, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01619.x · Cited by 53
Self-citationFang, J. Q., Deng, D., Nakamura, H., Akuta, T., Qin, H., Iyer, A. K., Greish, K. F., & Maeda, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22982 · Cited by 50
Self-citationMaruo, K., Akaike, T., Inada, Y., Ohkubo, I., Ono, T., & Maeda, H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46762-7 · Cited by 48
Self-citationNakamura, H., Randárová, E., Chytil, P., Tsukigawa, K., Fang, J. Q., Haratake, M., Ulbrich, K., Etrych, T., & Maeda, H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00697 · Cited by 46
Self-citationDaruwalla, J., Greish, K. F., Malcontenti‐Wilson, C., Muralidharan, V., Iyer, A. K., Maeda, H., & Christophi, C. (2008) · Journal of Vascular Research · doi:10.1159/000165380 · Cited by 43
Self-citationHarnessing Extracellular Matrix Biology for Tumor Drug Delivery
Subrahmanyam, N., & Ghandehari, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020088 · Cited by 42
Fang, J. Q., Šubr, V., Islam, W., Hackbarth, S., Islam, R., Etrych, T., Ulbrich, K., & Maeda, H. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.005 · Cited by 38
Self-citationMiyamoto, Y., Oda, T., & Maeda, H. (1990) · PubMed · Cited by 37
Self-citationFang, J. Q., Greish, K. F., Qin, H., Liao, L., Nakamura, H., Takeya, M., & Maeda, H. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.016 · Cited by 36
Self-citationFang, J. Q., Liao, L., Yin, H., Nakamura, H., Šubr, V., Ulbrich, K., & Maeda, H. (2015) · Future Science OA · doi:10.4155/fso.15.2 · Cited by 34
Self-citationMei, T., Shashni, B., Maeda, H., & Nagasaki, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120290 · Cited by 33
Self-citationOda, T., Sato, F., & Maeda, H. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.6.1205 · Cited by 33
Self-citationHerrmann, H., Kneidinger, M., Cerny‐Reiterer, S., Rülicke, T., Willmann, M., Gleixner, K. V., Blatt, K., Hoermann, G., Peter, B., Samorapoompichit, P., et al. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912798888992 · Cited by 32
Self-citationIslam, W., Matsumoto, Y., Fang, J. Q., Harada, A., Niidome, T., Ono, K., Tsutsuki, H., Sawa, T., Imamura, T., Sakurai, K., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120631 · Cited by 32
Self-citationSeymour, L. W., Olliff, S. P., Poole, C. J., de Takats, P. G., Orme, R., Ferry, D., Maeda, H., Konno, T., & Kerr, D. J. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.6.1217 · Cited by 28
Self-citationProtective Role of d -Amino Acid Oxidase against Staphylococcus aureus Infection
Nakamura, H., Fang, J. Q., & Maeda, H. (2012) · Infection and Immunity · doi:10.1128/iai.06214-11 · Cited by 28
Self-citationA New Tactic for the Treatment of Jaundice: An Injectable Polymer-Conjugated Bilirubin Oxidase
Kimura, M., Matsumura, Y., Miyauchi, Y., & Maeda, H. (1988) · Experimental Biology and Medicine · doi:10.3181/00379727-188-42747 · Cited by 28
Self-citationFang, J. Q., Iyer, A. K., Seki, T., Nakamura, H., Greish, K. F., & Maeda, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.006 · Cited by 27
Self-citationFang, J. Q., Tsukigawa, K., Liao, L., Yin, H., Eguchi, K., & Maeda, H. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1077851 · Cited by 25
Self-citationNakamura, H., Randárová, E., Chytil, P., Etrych, T., Haratake, M., & Maeda, H. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00248 · Cited by 21
Self-citationNewly Developed Self-Assembling Antioxidants as Potential Therapeutics for the Cancers
Shashni, B., & Nagasaki, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020092 · Cited by 20
Hadzijusufovic, E., Rebuzzi, L., Gleixner, K. V., Ferenc, V., Peter, B., Kondo, R., Gruze, A., Kneidinger, M., Krauth, M., Mayerhofer, M., et al. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.06.002 · Cited by 19
Self-citationDrug delivery research in Europe
Lammers, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.019 · Cited by 14
Nakamura, H., Fang, J. Q., Mizukami, T., Nunoi, H., & Maeda, H. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.011360 · Cited by 9
Self-citationBryan (1984) · doi:10.1002/1097-0142(19841201)54:11
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Pasut, G., and Zalipsky, S. (2020). Overcoming barriers for tumor-targeted drug delivery: The power of macromo-lecular anticancer drugs with the EPR effect and the modulation of vascular physiology. Polymer-Protein Conjugation: From PEGylation and Beyond, Elsevier.
- Maeda, 2015, Great expectations for innovative PDT and tumor imaging using fluorescing nanophotosensitizers that utilizes EPR effect, JSMI Rep., 9, 3
Cited by
Sorted by citations
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986
Filippov, S. K., Рамисович, Х. Р., Murmiliuk, A., Inam, W., Zakharova, L. Y., Zhang, H., & Khutoryanskiy, V. V. (2023) · Materials Horizons · doi:10.1039/d3mh00717k · Cited by 587
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet‐Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 537
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 474
Metadata
- Authors
- Maeda, H.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Maeda, Hiroshi
- ORCID
- Maeda, Hiroshi
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-03-22
- Volume
- 11
- Issue
- 3
- Pages
- 229
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8004895
- OpenAlex
- W3138405372
- Cited by
- 167
- References
- 87
- Citations by year
- 2026: 24 · 2025: 23 · 2024: 29 · 2023: 35 · 2022: 40 · 2021: 15
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (18H04059, 29400001)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- enhanced permeability and retention effect, anticancer drug delivery, nanomedicine, tumor perfusion, tumor vasculature, arterial infusion, tumor emboli, tumor necrosis, photodynamic therapy, boron neutron capture therapy, cancer chemotherapy, personalized medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
